Medical Marijuana, Inc. Subsidiary HempMeds® Announces Updated Branding Strategy to Accompany Change in Executive Leadership
SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- via -- (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary has launched the rebranding of its globally recognized hemp-derived cannabidiol (CBD) products as part of its recent shift in consumer strategy and executive leadership.
“As the CBD industry continues to expand exponentially throughout the world, especially in the US and Latin America, we saw an opportunity to further leverage Raul Elizalde's tremendous experience in the CBD industry by positioning him as the sole CEO of HempMeds. This is an exciting new direction for the Company which comes with new initiatives and activities such as updated branding, new products and digital events in 2021,” said HempMeds® Co-Founder Michelle Sides. “We are confident that consumers will respond positively to the new HempMeds branding as we continue pushing the industry forward as have since founding the company to help trailblaze the CBD market many years ago.”
The HempMeds® rebranding includes a new website, updated Company logos, new product formulations and refreshed packaging that aim to serve as more consumer-friendly, easy to understand and appeal to a wide audience. As part of the rebranding, the Company will be reformulating its RSHO® product line, which helped launch the global CBD industry, for increased absorption. The Company is also revealing two new products, one containing cannabigerol (CBG) and one containing cannabinol (CBN). The new products will expand the Company’s cannabinoid offerings and appeal to consumers’ changing demand.
“After many years of fighting for broadened access to CBD around the globe, cannabinoids have finally been accepted into mainstream culture in the U.S. and other countries around the world,” said HempMeds® CEO Raul Elizalde. “With this rebranding, we aim to show that we are constantly changing to match the world’s shift toward CBD and that our products are meant for use by all consumers while maintaining our high quality.”
Additionally, HempMeds® is in the process of selecting highly respected professionals for its Medical Advisory Board, which will aid in advising the Company’s expansion.
View the updated HempMeds® website at and shop the entire line of HempMeds®’s newly rebranded products at .
About HempMeds®
Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit
About Medical Marijuana, Inc.
Medical Marijuana, Inc. () is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by and ; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including and Medical Marijuana, Inc. was named a top CBD producer by . Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting .
To see Medical Marijuana, Inc.'s corporate video,.
Shareholders and consumers are also encouraged to.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:
Public Relations Contact:
Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
Investor Relations Contact:
P. (858) 283-4016
Attachment
